Notice of the Cambridge biotech's layoffs came less than two weeks after Sage announced it would be acquired by ...

Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks ...

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being canned, ...

Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Biogen paid Sage $11 million in collaboration revenues in the third quarter, during which the drug made $22 million, and buying Sage would give it total control of the brand.

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

The agreement comes after Sage filed a lawsuit to block a $469 million takeover from Biogen, its longstanding partner for Zurzuvae, saying the offer significantly undervalued its business.

The growing global burden of neuropsychiatric disorders is a critical driver for the treatment market. With over 9.1 million annual deaths attributed to neurological diseases and an additional 8 ...

Sage Therapeutics and Biogen equally share profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan, Taiwan ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

After rejecting a buyout offer from its partner Biogen, the Cambridge firm is being acquired by Supernus Pharmaceuticals.